Thursday, August 7, 2008
InNexus Biotechnology Announces Launch of Large Scale Primate Study of DXL625

Wednesday, August 6, 2008
InNexus Biotechnology Announces Third Antibody and Expands Pipeline of Anticancer Compounds

Thursday, July 31, 2008
InNexus To Present at 2008 DDT Aug 6th in Boston

Monday, June 23, 2008
InNexus Biotechnology Announces Completion of Brokered Private Placement

Monday, June 12, 2008
InNexus Biotechnology Announces Expansion of Patent Protection of DXL™ Technology

Monday, June 2, 2008
InNexus Biotechnology Launches Competitive Summer Intern Program: LABapprentice

Friday, May 30, 2008
InNexus Biotechnology Announces Oversubscription of Private Placement Raised to $5 Million and Additional Equity Financing up to $7.5 Million

Friday, May 23, 2008
InNexus Biotechnology Announces Brokered Private Placement with Dundee Securities Corporation

Wednesday, May 8, 2008
InNexus Biotechnology Hosts Inaugural Event of U.S. Department of Commerce

Wednesday, May 7, 2008
InNexus Biotechnology Receives 2008 Frost & Sullivan Innovation of the Year Award

Tuesday, April 15, 2008
InNexus Biotechnology Presents Proof of Principle Data at AACR

InNexus Biotechnology Inc. is a drug development company commercializing the next generation of monoclonal antibodies based on its Dynamic Cross Linking technology (DXL™) improving the potency of existing antibody products while opening new markets and disease applications.

»Recent Letter from the Chairman

»Watch BNN TV interview with CEO - Jeff Morhet

»Meet the Scientific Advisory Board

»See What InNexus Presented at AACR 2008 in San Diego